NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
IUPAC name
|
methyl N-(6-benzoyl-1H-1,3-benzodiazol-2-yl)carbamate
|
methyl N-(5-benzoyl-1H-1,3-benzodiazol-2-yl)carbamate
|
|
|
IUPAC Traditional name
|
telmin
|
mebendazole
|
methyl N-(6-benzoyl-1H-1,3-benzodiazol-2-yl)carbamate
|
vermox
|
|
|
Brand Name
|
Vermirax
|
Vermox
|
Vermox (TN)
|
Verpanyl
|
Bantenol
|
Besantin
|
Equivurm Plus
|
Lomper
|
MBDZ
|
MEBENDAZOLE, 99%
|
Mebendazole (JAN/USP)
|
Mebendazole(USAN)
|
Mebenoazole
|
Mebenvet
|
Mebex
|
Mebutar
|
Noverme
|
Ovitelmin
|
Pantelmin
|
Telmin
|
Vermicidin
|
|
|
Synonyms
|
Mebendazole
|
N-(6-Benzoyl-1H-benzimidazol-2-yl)carbamic Acid Methyl Ester
|
Bantenol
|
Besantin
|
Mebenvet
|
Mebex
|
Noverme
|
Ovitelmin
|
Pantelmin
|
R 17635
|
methyl N-(6-benzoyl-1H-1,3-benzodiazol-2-yl)carbamate
|
5-benzoyl-2-benzimidazolylcarbamic acid methyl ester
|
Equivurm Plus
|
Lomper
|
MBDZ
|
Mebenoazole
|
Mebutar
|
Telmin
|
Vermicidin
|
Vermirax
|
Vermox
|
Verpanyl
|
Mebendazole
|
methyl (5-benzoyl-1H-benzo[d]imidazol-2-yl)carbamate
|
5-Benzoyl-2-benzimidazolecarbamic acid methyl ester
|
Mebendazol
|
Methyl N-(5-benzoyl-1H-benzimidazol-2-yl)carbamate
|
methyl (5-benzoyl-1H-benzimidazol-2-yl)carbamate
|
5-苯甲酰-2-苯并咪唑胺甲酸甲酯
|
N-(5-苯甲酰-1H-苯并咪唑-2-基)氨基甲酸甲酯
|
甲苯咪唑
|
甲苯达唑
|
|
|
CAS Number
|
|
EC Number
|
|
MDL Number
|
MFCD00408814
|
MFCD00057872
|
|
|
Beilstein Number
|
|
PubChem SID
|
|
PubChem CID
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
ALOGPS 2.1
Acid pKa
|
9.168718
|
H Acceptors
|
4
|
H Donor
|
2
|
LogD (pH = 5.5)
|
3.2565598
|
LogD (pH = 7.4)
|
3.2536292
|
Log P
|
3.2601085
|
Molar Refractivity
|
81.5039 cm3
|
Polarizability
|
31.87077 Å3
|
Polar Surface Area
|
84.08 Å2
|
Rotatable Bonds
|
4
|
Lipinski's Rule of Five
|
true
|
Log P
|
2.95
|
LOG S
|
-3.88
|
Solubility (Water)
|
3.87e-02 g/l
|
DETAILS
DETAILS
DrugBank
Sigma Aldrich
TRC
DrugBank -
DB00643
|
Item |
Information |
Drug Groups
|
approved |
Description
|
A benzimidazole that acts by interfering with carbohydrate metabolism and inhibiting polymerization of microtubules. [PubChem] |
Indication |
For the treatment of Enterobius vermicularis (pinworm), Trichuris trichiura (whipworm), Ascaris lumbricoides (common roundworm), Ancylostoma duodenale (common hookworm), Necator americanus (American hookworm) in single or mixed infections. |
Pharmacology |
Mebendazole is a (synthetic) broad-spectrum anthelmintic. The principal mode of action for Mebendazole is by its inhibitory effect on tubulin polymerization which results in the loss of cytoplasmic microtubules. |
Toxicity |
Acute oral toxicity (LD50): 620 mg/kg [Mouse]. Symptoms of overdose include elevated liver enzymes, headaches, hair loss, low levels of white blood cells (neutropenia), fever, and itching. |
Affected Organisms |
• |
Helminthic Microorganisms |
|
Biotransformation |
Primarily hepatic. Primary metabolite is 2-amino-5-benzoylbenzimidazole, but also metabolized to inactive hydroxy and hydroxyamino metabolites. All metabolites are devoid of anthelmintic activity. |
Absorption |
Poorly absorbed (approximately 5 to 10%) from gastrointestinal tract. Fatty food increases absorption. |
Half Life |
2.5 to 5.5 hours (range 2.5 to 9 hours) in patients with normal hepatic function. Approximately 35 hours in patients with impaired hepatic function (cholestasis). |
Protein Binding |
90-95% |
Elimination |
In man, approximately 2% of administered mebendazole is excreted in urine and the remainder in the feces as unchanged drug or a primary metabolite. |
References |
|
External Links |
|
|
PATENTS
PATENTS
PubChem Patent
Google Patent